Home   News   Article

King's Lynn solicitor takes part in Novavax trial for new jab, which claims to have 89.3% efficacy with new variant



More news, no ads

LEARN MORE


Lisa Austin, 34, a solicitor at Ward Gethin Archer in Lynn took part in the Novavax clinical trials for a new Covid-19 vaccine due to be rolled out later this year.

Novavax have been working on a new protein based vaccine that claims an 89.3 per cent efficacy with the new variant and has shown positive results in phase two trials in South Africa against the most recent variant seen in Kent, called the South Africa Escape strain.

Lisa Austin took part in the Novavax vaccine clinical trials last October. Picture: Ian Burt. (44194998)
Lisa Austin took part in the Novavax vaccine clinical trials last October. Picture: Ian Burt. (44194998)

Lisa decided to take part in the trials as a way to help others during the pandemic: "I didn't feel there was much else I could do, so I signed up with the NHS and next thing I knew I was getting the jab."

Many have been concerned over the new vaccine's side effects, however Lisa reported that in her own experience she had nothing more than a 'sore arm'.

"I honestly thought I was part of the placebo group until I was told otherwise. Everyone reacts differently, I couldn't speak for others, but I personally had no adverse effects and wouldn't hesitate to recommend it to family and friends."

Lisa said she wasn't nervous and her family is proud of her for taking part: "My mum was a bit worried but my husband is glad I've done it."

The UK Government is poised to go ahead with the purchase of 100million Novavax vaccines this year, once it has been fully approved and start a UK based production in Stockton-on-Tees.

The benefit of this new jab is that it can be stored between 2C and 8C, which is refrigerator temperature, allowing for easier transportation and storage.

The study enrolled more than 15,000 participants between 18-84 years of age, including 27 per cent over the age of 65.

The primary endpoint of the UK phase three clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) Covid-19 with onset at least seven days after the second study vaccination in serologically Covid-19 negative adult participants at baseline.

“These are spectacular results, and we are very pleased to have helped Novavax with the development of this vaccine.

"The efficacy shown against the emerging variants is also extremely encouraging. This is an incredible achievement that will ensure we can protect individuals in the UK and the rest of the world from this virus,” said Clive Dix, chairman of the UK Vaccine Taskforce.



This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More